| Dr Paulo M Gazoni, MD | |
|
5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226-1907 | |
| (804) 287-7066 | |
| (804) 673-9531 |
| Full Name | Dr Paulo M Gazoni |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 24 Years |
| Location | 5801 Bremo Rd, Richmond, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063455335 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0101232953 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical College Of Virginia Hospitals | Richmond, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcv Associated Physicians | 4385542117 | 1312 |
News Archive
New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
Springer and the Italian Society for the Study of Eating Disorders (Societ- Italiana per lo Studio dei Disturbi del Comportamento Alimentare - SISDCA) have agreed to a five-year collaboration to publish the quarterly journal Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, starting in 2013 with Volume 18. As the official journal of SISDCA, it will be available exclusively in electronic format on SpringerLink.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.
› Verified 8 days ago
| Entity Name | Mcv Associated Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710959457 PECOS PAC ID: 4385542117 Enrollment ID: O20031230000559 |
News Archive
New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
Springer and the Italian Society for the Study of Eating Disorders (Societ- Italiana per lo Studio dei Disturbi del Comportamento Alimentare - SISDCA) have agreed to a five-year collaboration to publish the quarterly journal Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, starting in 2013 with Volume 18. As the official journal of SISDCA, it will be available exclusively in electronic format on SpringerLink.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.
› Verified 8 days ago
| Entity Name | Emergency Physicians Immediate Care Center 1 Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598020679 PECOS PAC ID: 0941452833 Enrollment ID: O20121128000170 |
News Archive
New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
Springer and the Italian Society for the Study of Eating Disorders (Societ- Italiana per lo Studio dei Disturbi del Comportamento Alimentare - SISDCA) have agreed to a five-year collaboration to publish the quarterly journal Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, starting in 2013 with Volume 18. As the official journal of SISDCA, it will be available exclusively in electronic format on SpringerLink.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.
› Verified 8 days ago
| Entity Name | Emergency Physicians Immediate Care Center 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992138820 PECOS PAC ID: 0941438758 Enrollment ID: O20140123001807 |
News Archive
New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
Springer and the Italian Society for the Study of Eating Disorders (Societ- Italiana per lo Studio dei Disturbi del Comportamento Alimentare - SISDCA) have agreed to a five-year collaboration to publish the quarterly journal Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, starting in 2013 with Volume 18. As the official journal of SISDCA, it will be available exclusively in electronic format on SpringerLink.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paulo M Gazoni, MD 5855 Bremo Road, Suite 210, Richmond, VA 23226-1922 Ph: () - | Dr Paulo M Gazoni, MD 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226-1907 Ph: (804) 287-7066 |
News Archive
New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
Springer and the Italian Society for the Study of Eating Disorders (Societ- Italiana per lo Studio dei Disturbi del Comportamento Alimentare - SISDCA) have agreed to a five-year collaboration to publish the quarterly journal Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, starting in 2013 with Volume 18. As the official journal of SISDCA, it will be available exclusively in electronic format on SpringerLink.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.
› Verified 8 days ago
Robert Weisberger, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Dr. Michael Ferebee, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1602 Skipwith Rd, Richmond, VA 23229 Phone: 757-329-3754 | |
James R Shefferly, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Jeffry A Zimmerman, P.A. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5801 Bremo Rd, St Francis Emergency Department, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Shawn M Borich, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Rockbridge St Ste 103, Richmond, VA 23230 Phone: 804-386-0200 | |
Tamera Barnes, MD, FACEP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7101 Jahnke Rd, Richmond, VA 23225 Phone: 804-330-2000 | |
Dr. Kevin James Noreika, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1401 Johnston Willis Dr, Richmond, VA 23235 Phone: 804-330-2277 |